Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | DGKA | P23743 | 1/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 7/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1837065 | 0.84 | LMNA (0.44) | MEN1KMT2ACYP4F2CYP4A11 | |
| SCHEMBL6871664 | 0.82 | MEN1 (0.59) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL6863717 | 0.81 | NAAA (0.48) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL28713995 | 0.77 | CYP4F2 (0.50) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL6870963 | 0.76 | MAPT (0.42) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL6873197 | 0.76 | MEN1 (0.57) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL6873127 | 0.76 | MEN1 (0.47) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL2461067 | 0.76 | CYP4F2 (0.43) | CES2MEN1MAPTKMT2AATM | |
| SCHEMBL1784700 | 0.76 | KMT2A (0.35) | KMT2ACYP4F2CYP4A11 | |
| SCHEMBL6753228 | 0.75 | NAAA (0.47) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165633-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2004-07-14 | — | — | EP | claimed |
| US-6716939-B2 | COMPRISING TITANIUM, MAGNESIUM, HALOGEN AND AN ELECTRON DONOR COMPOUND SELECTED FROM ESTERS OF SUBSTITUTED SUCCINIC ACIDS | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2004-04-06 | — | — | US | claimed |
| US-20020183575-A1 | Components and catalysts for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2002-12-05 | — | — | US | claimed |
| EP-1165633-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | Basell Technology Company B.V. (NL) | 2002-01-02 | — | — | EP | claimed |
| WO-2001057099-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL TECHNOLOGY COMPANY B.V. (NL) | 2001-08-09 | — | — | WO | claimed |
| EP-1165633-B1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE SPA (IT) | 2004-07-14 | — | — | EP | disclosed |
| US-6716939-B2 | COMPRISING TITANIUM, MAGNESIUM, HALOGEN AND AN ELECTRON DONOR COMPOUND SELECTED FROM ESTERS OF SUBSTITUTED SUCCINIC ACIDS | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2004-04-06 | — | — | US | disclosed |
| US-20020183575-A1 | Components and catalysts for the polymerization of olefins | BASELL POLIOLEFINE ITALIA S.P.A. (IT) | 2002-12-05 | — | — | US | disclosed |
| EP-1165633-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | Basell Technology Company B.V. (NL) | 2002-01-02 | — | — | EP | disclosed |
| WO-2001057099-A1 | COMPONENTS AND CATALYSTS FOR THE POLYMERIZATION OF OLEFINS | BASELL TECHNOLOGY COMPANY B.V. (NL) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183575-A1 | Components and catalysts for the polymerization of olefins | SCO2, ECI1, MT-CO2 | CES2 2121/4885MEN1 4525/4885MAPT 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.